uniQure N.V. (NASDAQ:QURE) saw unusually large options trading activity on Wednesday. Stock investors acquired 3,043 call options on the stock. This is an increase of 806% compared to the typical volume of 336 call options.
QURE has been the subject of several research reports. Zacks Investment Research cut shares of uniQure N.V. from a “buy” rating to a “hold” rating in a research note on Thursday, August 24th. Leerink Swann raised their target price on shares of uniQure N.V. from $19.00 to $26.00 in a research note on Tuesday, November 7th. Evercore ISI initiated coverage on shares of uniQure N.V. in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $22.00 target price for the company. Finally, ValuEngine cut shares of uniQure N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. uniQure N.V. has an average rating of “Buy” and an average target price of $17.43.
uniQure N.V. (NASDAQ:QURE) opened at $15.81 on Friday. uniQure N.V. has a 52 week low of $4.72 and a 52 week high of $21.35. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73.
ILLEGAL ACTIVITY WARNING: “Traders Buy High Volume of uniQure N.V. Call Options (QURE)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/25/traders-buy-high-volume-of-uniqure-n-v-call-options-qure.html.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
What are top analysts saying about uniQure N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for uniQure N.V. and related companies.